In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China Revokes Licenses For Shanghai Hualian Leukemia Drugs Found Contaminated (China)

This article was originally published in PharmAsia News

Executive Summary

China revoked the license of Shanghai Hualian Pharmaceutical in the wake of an investigation that found it was marketing contaminated leukemia drugs that harmed patients. The company's license was canceled and the employees responsible have been detained, according to the State FDA. The agency accused the employees of a "systematically organized" cover-up during the government investigation of a case of several children injected with methotrexate who developed leg pains and difficulty walking. Use of the drug and another based on cytarabin hydrochloride were ordered suspended in September. The parent company, Shanghai Pharmaceutical Group, was ordered to compensate the families of the patients. (Click here for more ) "Cancer Drug Company Slammed After Probe" Shanghai Daily (China) (12/13/07)

You may also be interested in...



Keeping Track: US FDA Clears Esperion’s Nexletol, Baudax’ Anjeso, Agile’s Twirla

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Esperion’s Nexletol Reaches The Cholesterol Market Priced To Sell

Esperion obtained an on-time approval of Nexletol (bempedoic acid) for a pair of LDL cholesterol-lowering indications on 21 February. 

Pharmacogenetic Tests: US FDA Tries Off-Label Approach To Guide Consumers

US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.

UsernamePublicRestriction

Register

SC065865

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel